Molecular Diagnostics: Drivers of New Investor Interest and Reimbursement Success

10:45 AM - 11:40 AM, Wednesday, October 23, 2019 ・ 2nd Floor
As the biotechnology industry continues to address unmet medical needs across a wide variety of diseases and disorders, emerging innovative diagnostics methods are paving the way for earlier detection and increased levels of response to treatment. Companion and molecular diagnostics offer advanced methods of identifying biomarkers for cancer and other diseases and allow for the application of bespoke immune-based therapies. Additionally, Diagnostics Analytics deals spiked in the first half of 2019, with 119 deals totaling $2.164 billion, and are predicted to continue a three-year upward trend, according to the Silicon Valley Bank Mid-Year Report 2019. This panel explores the novel drug and product development from diagnostics companies in the industry that drive funding and reimbursement.
Illumina Ventures
Co-founder, CEO
Mammoth Biosciences
Senior Vice President of In Vitro Diagnostics and Quality
Precision for Medicine
Global Search and Evaluation Lead
Bristol-Myers Squibb
Chief Medical Officer
Epic Sciences